Kolon’s Invossa-K Phase 3 clinical trial to continue after FDA nod
Category: #health  By Saipriya Iyer  Date: 2020-04-13
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Kolon’s Invossa-K Phase 3 clinical trial to continue after FDA nod

Kolon Life Science has announced that it has received an approval to continue Invossa-K’s phase-3 clinical trial by the U.S. Food and Drug Administration. Invossa-K is a gene therapy for osteoarthritis and the trial is being run in the United States. 

Apparently, the FDA gave its approval for the drug test nearly a year after it had suspended the study. The Korean regulator had revoked the Invossa license on account of an ingredient mislabeling. The latest decision made by the FDA has given Kolon a fresh start concerning the Invossa business.

The FDA had sent an official notice to a Kolon Life Science subsidiary, Kolon TissueGene, that it will be removing the clinical hold on the Invossa’s phase 3 trial. As per the Kolon TissueGene, the FDA stated that the issues regarding the clinical hold had been resolved and the firm will be able to continue with the Invossa clinical trial.

Kolon had initiated Invossa’s phase-3 study on October 30 in 2018 in the U.S., which was later suspended by the FDA in 2019. The firm had admitted that the cell ingredient that came from the second fluid of the drug had not been derived from the cartilage but the kidney, which is also called GP2-293. The company had submitted the extra data twice for clearance from the regulatory body.

According to sources familiar with the matter, the FDA had requested the firm to submit supplementary materials that also include the ingredients of Invossa like the evaluation of the cell’s identity covering the way the drug composition has changed and the forthcoming measures. The regulator had demanded for analysis of the properties of Invossa ingredients.

The FDA has asked the firm to submit data placed on the stability of all the clinical samples as well as the improvement measures for the production process of Invossa.

 

Source credit- http://www.koreabiomed.com/news/articleView.html?idxno=7986



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...